Find your next paid study

Immunome, Inc.NCT06823167

~$150 – $4,200

Actual pay is set by the research site.

Hematologic MalignancyAcute LeukemiaRemission+21 more

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for c…

Actual pay is set by the research site.

Phase 1

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle ce…

Hematological Malignancy

M.D. Anderson Cancer CenterNCT05110742

~$150 – $3,000

Actual pay is set by the research site.

Phase 3

An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indicati…

Hematologic MalignancySolid TumorAdvanced Malignancies

Novartis PharmaceuticalsNCT06401356

~$50 – $2,100

Actual pay is set by the research site.

Phase 1

A Phase I Trial of Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

To determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-1…

Hematologic Diseases

Roswell Park Cancer InstituteNCT07701889

~$150 – $4,500

Actual pay is set by the research site.

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often …

B-ALLHematologic MalignancySolid Tumor

St. Jude Children's Research HospitalNCT06579469

~$10 – $750

Actual pay is set by the research site.

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Milton S. Hershey Medical CenterNCT06926595

Actual pay is set by the research site.

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infe…

Northside Hospital, Inc.NCT04237623

Actual pay is set by the research site.

Observational

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymp…

Hematologic MalignancyBlood CancerLymphoma+2 more

Massachusetts General HospitalNCT05646576

~$10 – $750

Actual pay is set by the research site.

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Hematologic MalignancySolid Malignancy

CRISPR Therapeutics AGNCT06208878

~$10 – $1,050

Actual pay is set by the research site.

Hematologic Disease and DisordersHematopoietic Cell Transplant

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier…

Northside Hospital, Inc.NCT06828796

Actual pay is set by the research site.

Observational

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in pati…

Hematologic DisordersHemoglobinopathiesImmunodeficiencies